Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Management of Metastatic Carcinoid Tumors

  • Chapter
  • First Online:
Neuroendocrine Tumors

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

For patients with localized carcinoid tumors, surgical resection alone is often curative. Patients with metastatic disease, on the other hand, often present a therapeutic challenge. While somatostatin analogs are highly effective in controlling symptoms of hormonal secretion, they are only rarely associated with tumor regression. Selected patients with hepatic metastases may benefit from surgical ­debulking, embolization, or other ablative therapies. The clinical benefit associated with the administration of systemic agents such as alpha interferon or cytotoxic chemotherapy is less clear, and the widespread use of such regimens has been ­limited by their relatively modest anti-tumor activity as well as concerns regarding their potential toxicity. New treatment approaches for patients with metastatic carcinoid tumors are being actively explored.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Harpole D, Feldman J, Buchanan S, et al. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg. 1992;54:50–5.

    Article  PubMed  Google Scholar 

  2. Vadasz P, Palffy G, Egervary M, et al. Diagnosis and treatment of bronchial carcinoid tumors: clinical and pathological review of 120 operated patients. Eur J Cardiothorac Surg. 1993;7:8–11.

    Article  PubMed  CAS  Google Scholar 

  3. Okike N, Bernatz P, Woolner L. Carcinoid tumors of the lung. Ann Thorac Surg. 1976;22:270–7.

    Article  PubMed  CAS  Google Scholar 

  4. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from literature. Chest. 2001;119:1647–51.

    Article  PubMed  CAS  Google Scholar 

  5. Oberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst. 1989;81:531–5.

    Article  PubMed  CAS  Google Scholar 

  6. McCaughan B, Martini N, Bains M. Bronchial carcinoids: review of 124 cases. J Thorac Cardiovasc Surg. 1985;89:8–17.

    PubMed  CAS  Google Scholar 

  7. Chughtai T, Morin J, Sheiner N, et al. Bronchial carcinoid-twenty years’ experience defines a selective surgical approach. Surgery. 1997;122:801–8.

    Article  PubMed  CAS  Google Scholar 

  8. Skuladottir H, Hirsch F, Hansen H, et al. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer. 2002;37:127–35.

    Article  PubMed  Google Scholar 

  9. Torre M, Barberis M, Barbieri B, et al. Typical and atypical bronchial carcinoids. Respir Med. 1989;83:305–8.

    Article  PubMed  CAS  Google Scholar 

  10. Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104:994–1006.

    PubMed  CAS  Google Scholar 

  11. Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20:168–72.

    Article  PubMed  CAS  Google Scholar 

  12. Barclay T, Schapira D. Malignant tumors of the small intestine. Cancer. 1983;51:878–81.

    Article  PubMed  CAS  Google Scholar 

  13. Moertel C, Sauer W, Dockerty M, et al. Life history of the carcinoid tumor of the small ­intestine. Cancer. 1961;14:901–12.

    Article  PubMed  CAS  Google Scholar 

  14. Burke AP, Thomas RM, Elsayed AM, et al. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer. 1997;79:1086–93.

    Article  PubMed  CAS  Google Scholar 

  15. Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14:377–85.

    Article  PubMed  CAS  Google Scholar 

  16. Eckhauser FE, Argenta LC, Strodel WE, et al. Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery. 1981;90:720–8.

    PubMed  CAS  Google Scholar 

  17. Hellman P, Lundstrom T, Ohrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26:991–7.

    Article  PubMed  Google Scholar 

  18. Moertel C, Dockerty M, Judd E. Carcinoid tumors of the vermiform appendix. Cancer. 1968;21:270–8.

    Article  PubMed  CAS  Google Scholar 

  19. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–59.

    Article  PubMed  Google Scholar 

  20. Moertel CG, Weiland LH, Nagorney DM, et al. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med. 1987;317:1699–701.

    Article  PubMed  CAS  Google Scholar 

  21. Anderson J, Wilson B. Carcinoid tumors of the appendix. Br J Surg. 1985;72:545–6.

    Article  PubMed  CAS  Google Scholar 

  22. Syracuse D, Perzin K, Weidel P, et al. Carcinoid tumors of the appendix: mesoappendiceal extension and nodal metastases. Ann Surg. 1979;190:58–63.

    Article  PubMed  CAS  Google Scholar 

  23. Bowman G, Rosenthal D. Carcinoid tumors of the appendix. Am J Surg. 1983;146:700–3.

    Article  PubMed  CAS  Google Scholar 

  24. Thirlby R, Kasper C, Jones R. Metastatic carcinoid tumor of the appendix: report of a case and review of the literature. Dis Colon Rectum. 1984;27:42–6.

    Article  PubMed  CAS  Google Scholar 

  25. MacGillivray D, Heaton R, Rushin J, et al. Distant metastases from a carcinoid tumor of the appendix less than one centimeter in size. Surgery. 1992;111:466–71.

    PubMed  CAS  Google Scholar 

  26. Pearlman D, Srinivasan K. Malignant carcinoid of the appendix: metastases from a small primary tumor which appeared as appendiceal intussusception. N Y State J Med. 1971;71:1529–31.

    PubMed  CAS  Google Scholar 

  27. Jetmore A, Ray J, Gathright J, et al. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum. 1992;35:717–25.

    Article  PubMed  CAS  Google Scholar 

  28. Soga J. Carcinoids of the rectum: tumors of the carcinoid family-urgut endocrinomas. Acta Med Biol. 1982;29:157–201.

    Google Scholar 

  29. Naunheim K, Zeitels J, Kaplan E, et al. Rectal carcinoid tumors – treatment and prognosis. Surgery. 1983;94:670–6.

    PubMed  CAS  Google Scholar 

  30. Woodard P, Feldman J, Paine S, et al. Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr. 1995;19:400–5.

    Article  PubMed  CAS  Google Scholar 

  31. Sugimoto E, Lorelius L, Eriksson B, et al. Midgut carcinoid tumors: CT appearance. Radiologica. 1995;36:367–71.

    CAS  Google Scholar 

  32. Lamberts S, Bakker W, Reubi J, et al. Somatostatin receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990;323:1246–9.

    Article  PubMed  CAS  Google Scholar 

  33. Kvols LK, Brown ML, O’Connor MK, et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology. 1993;187:129–33.

    PubMed  CAS  Google Scholar 

  34. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclites in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902.

    Article  PubMed  CAS  Google Scholar 

  35. Krenning E, Kwekkeboom D, Bakker W, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] - and [123-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31.

    Article  PubMed  CAS  Google Scholar 

  36. Schillaci O, Scopinaro F, Danieli R, et al. Single photon emission computerized tomography increases the sensitivity of indium-111-pentetreotide scintigraphy in detecting abdominal carcinoids. Anticancer Res. 1997;17:1753–6.

    PubMed  CAS  Google Scholar 

  37. Schillaci O, Corleto V, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol. 1999;31 Suppl 2:S186–9.

    PubMed  Google Scholar 

  38. Gibril F, Reynolds J, Doppman J, et al. Somatostatin receptor scintigraphy: its sensitivity compared to that of other imaging methods in detection of primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996;125:26–34.

    PubMed  CAS  Google Scholar 

  39. Feldman JM, O’Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986;81:41–8.

    Article  PubMed  CAS  Google Scholar 

  40. Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med. 1995;46:395–411.

    Article  PubMed  CAS  Google Scholar 

  41. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62 Suppl 1:33–8.

    Article  PubMed  CAS  Google Scholar 

  42. Janson E, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685–90.

    Article  PubMed  CAS  Google Scholar 

  43. Lundin L, Norheim I, Landelius J, et al. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988;77:264–9.

    Article  PubMed  CAS  Google Scholar 

  44. Simula D, Edwards W, Tazelaar H, et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. 2002;77:139–47.

    Article  PubMed  Google Scholar 

  45. Robiolio P, Rigolin V, Wilson J, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catherterization and echocardiography. Circulation. 1995;77:264–9.

    Google Scholar 

  46. Pellikka P, Tajik A, Khandheria B, et al. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188–96.

    PubMed  CAS  Google Scholar 

  47. Moller J, Connolly H, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348:1005–15.

    Article  PubMed  Google Scholar 

  48. Zuetenhorst J, Bonfrer J, Korse C, et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial antriuretic peptide, transforming growth factor beta and fibroblast growth factor. Cancer. 2003;97:1609–15.

    Article  PubMed  CAS  Google Scholar 

  49. Connolly H, Nishimura R, Smith H, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. 1995;25:410–6.

    Article  PubMed  CAS  Google Scholar 

  50. Voigt P, Braun J, Teng O, et al. Double bioprosthetic valve replacement in right sided carcinoid heart disease. Ann Thorac Surg. 2005;79:2147–9.

    Article  PubMed  Google Scholar 

  51. Que F, Nagorney D, Batts K, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36–43.

    Article  PubMed  CAS  Google Scholar 

  52. McEntee G, Nagorney D, Kvols L, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–6.

    PubMed  CAS  Google Scholar 

  53. Norton J, Warren R, Kelly M, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057–65.

    Article  PubMed  Google Scholar 

  54. Alsina A, Bartus S, Hull D, et al. Liver transplant for metastatic neuroendocrine tumor. J Clin Gastroenterol. 1990;12:533–7.

    Article  PubMed  CAS  Google Scholar 

  55. LeTreut Y, Delpero J, Dousset B. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31 case French multicentric report. Ann Surg. 1997;225:355–64.

    Article  CAS  Google Scholar 

  56. Lang H, Oldhafer K, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg. 1997;225:347–54.

    Article  PubMed  CAS  Google Scholar 

  57. Ajani J, Carrasco C, Charnsangavej C, et al. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med. 1988;108:340–4.

    PubMed  CAS  Google Scholar 

  58. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302–9.

    PubMed  CAS  Google Scholar 

  59. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993;71:2624–30.

    Article  PubMed  CAS  Google Scholar 

  60. Eriksson B, Larsson E, Skogseid B, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83:2293–301.

    Article  PubMed  CAS  Google Scholar 

  61. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9:261–7.

    Article  PubMed  Google Scholar 

  62. Dominguez S, Denys A, Madeira I, et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol. 2000;12:151–7.

    Article  PubMed  CAS  Google Scholar 

  63. Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg. 1998;175:408–12.

    Article  PubMed  CAS  Google Scholar 

  64. Diamandidou E, Ajani JA, Yang DJ, et al. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol. 1998;170:339–44.

    PubMed  CAS  Google Scholar 

  65. Loewe C, Schindl M, Cejna M, et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol. 2003;180:1379–84.

    PubMed  Google Scholar 

  66. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999;10:397–403.

    Article  PubMed  CAS  Google Scholar 

  67. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9.

    Article  PubMed  Google Scholar 

  68. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–9.

    Article  PubMed  Google Scholar 

  69. Hellman P, Ladjevardi S, Skogseid B, et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002;26:1052–6.

    Article  PubMed  Google Scholar 

  70. Chung MH, Pisegna J, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery. 2001;130:954–62.

    Article  PubMed  CAS  Google Scholar 

  71. Reubi J, Kvols L, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50:5969–77.

    PubMed  CAS  Google Scholar 

  72. Kvols L, Moertel C, O’Connell M, et al. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analog. N Engl J Med. 1986;315:663–6.

    Article  PubMed  CAS  Google Scholar 

  73. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600–6.

    PubMed  CAS  Google Scholar 

  74. Faiss S, Rath U, Mansmann U, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion. 1999;60:469–76.

    Article  PubMed  CAS  Google Scholar 

  75. Wymenga A, Eriksson B, Salmela P, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17:1111.

    PubMed  CAS  Google Scholar 

  76. O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88:770–6.

    Article  PubMed  Google Scholar 

  77. Ducreux M, Ruszniewski P, Chayvialle J, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide, interferon alpha, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Laureodtide and Interferon Alfa Study Group. Am J Gastroenterol. 2000;95:3276–81.

    Google Scholar 

  78. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689–96.

    Article  PubMed  CAS  Google Scholar 

  79. Janson ET, Kauppinen HL, Oberg K. Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial. Acta Oncol. 1993;32:231–3.

    Article  PubMed  CAS  Google Scholar 

  80. Frank M, Klose K, Wied M, et al. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol. 1999;94:1381–7.

    PubMed  CAS  Google Scholar 

  81. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med. 1983;309:129–33.

    Article  PubMed  CAS  Google Scholar 

  82. Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol. 1991;30:519–22.

    Article  PubMed  CAS  Google Scholar 

  83. Valimaki M, Jarvinen H, Salmela P, et al. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer. 1991;67:547–9.

    Article  PubMed  CAS  Google Scholar 

  84. Rinke A, Muller H, Schade-Brittinger C, et al. Placebo-controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–63.

    Article  PubMed  CAS  Google Scholar 

  85. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol. 1983;1:727–40.

    PubMed  CAS  Google Scholar 

  86. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials. 1979;2:327–34.

    PubMed  CAS  Google Scholar 

  87. Engstrom PF, Lavin PT, Moertel CG, et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol. 1984;2:1255–9.

    PubMed  CAS  Google Scholar 

  88. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897–904.

    Article  PubMed  CAS  Google Scholar 

  89. Bukowski R, Tangen C, Peterson R, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer. 1994;73:1505–8.

    Article  PubMed  CAS  Google Scholar 

  90. Bajetta E, Ferrari L, Procopio G, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumors. Ann Oncol. 2002;13:614–21.

    Article  PubMed  CAS  Google Scholar 

  91. Moertel C, Kvols L, O’Connell M, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.

    Article  PubMed  CAS  Google Scholar 

  92. Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001;92:1101–7.

    Article  PubMed  CAS  Google Scholar 

  93. Ansell SM, Pitot HC, Burch PA, et al. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001;91:1543–8.

    Article  PubMed  CAS  Google Scholar 

  94. Kulke MH, Kim H, Clark JW, et al. A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004;101:934–9.

    Article  PubMed  CAS  Google Scholar 

  95. Kulke MH, Kim H, Stuart K, et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004;22:353–9.

    Article  PubMed  CAS  Google Scholar 

  96. Kwekkeboom D, Bakker W, Kooij P, et al. 177Lu-DOTA, Tyr3 octreotate: comparison with [111In-DTPA] octreotide in patients. Eur J Nucl Med. 2001;28:1319–25.

    Article  PubMed  CAS  Google Scholar 

  97. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  PubMed  CAS  Google Scholar 

  98. Bushnell Jr DL, O’Dorisio TM, O’Dorisio MS, et al. 90Y-Edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652–9.

    Article  PubMed  CAS  Google Scholar 

  99. Terris B, Scoazec J, Rubbia L. Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology. 1998;32:133–8.

    Article  PubMed  CAS  Google Scholar 

  100. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26:1316–23.

    Article  PubMed  CAS  Google Scholar 

  101. Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol. 2007;2007 ASCO Annual Meeting Proceedings Part I. 25:Abstract 4505.

    Google Scholar 

  102. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–10.

    Article  PubMed  CAS  Google Scholar 

  103. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95:1148–54.

    Article  PubMed  CAS  Google Scholar 

  104. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study [erratum appears in J Clin Oncol. 2008;26(34):5660]. J Clin Oncol. 2008;26:4311–8.

    Article  PubMed  Google Scholar 

  105. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401–6.

    Article  PubMed  CAS  Google Scholar 

  106. Kelsen DP, Buckner J, Einzig A, et al. Phase II trial of cisplatin and etoposide in adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep. 1987;71:329–30.

    PubMed  CAS  Google Scholar 

  107. Bukowski RM, Johnson KG, Peterson RF, et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer. 1987;60:2891–5.

    Article  PubMed  CAS  Google Scholar 

  108. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110–22.

    Article  PubMed  Google Scholar 

  109. Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123–32.

    Article  PubMed  Google Scholar 

  110. Otte A, Herrmann R, Macke HR, et al. Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors. Schweiz Rundsch Med Prax. 1999; 88:1263–8.

    CAS  Google Scholar 

  111. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–34.

    Article  PubMed  CAS  Google Scholar 

  112. Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941–5.

    Article  PubMed  CAS  Google Scholar 

  113. Waldherr C, Pless M, Maecke H, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med. 2002;43:610–6.

    PubMed  CAS  Google Scholar 

  114. DeJong M, Valkema R, Jamar F, et al. Somatostatin-receptor targeted radionucleotide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133–40.

    Article  Google Scholar 

  115. Teunissen JJ, Kwekkeboom DJ, de Jong M, et al. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol. 2005; 19:595–616.

    Article  PubMed  CAS  Google Scholar 

  116. Virgolini I, Britton K, Buscombe J, et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148–55.

    Article  PubMed  Google Scholar 

  117. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62.

    Article  PubMed  CAS  Google Scholar 

  118. Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007;13:234–40.

    Article  PubMed  CAS  Google Scholar 

  119. Hobday T, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients with progressive metastatic neuroendocrine tumors: a phase II consortium study. J Clin Oncol. 2006;2006 ASCO Annual Meeting Proceedings 24:A4043.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA, 02115, USA

    Matthew H. Kulke

Authors
  1. Matthew H. Kulke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew H. Kulke .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, Department of Gastrointestinal, University of Texas, Holcombe Blvd. 1400, Houston, 77030-4009, Texas, USA

    James C. Yao

  2. São Paulo, Faculdade de Medicina da, Universidade de São Paulo,, Instituto do Cancer do Estado de, Ave Dr Arnaldo 251, São Paulo, 01246-000, São Paulo, Brazil

    Paulo M. Hoff

  3. Cancer do Estado de São Paulo, Faculdade, de Medicina da Universidade de São Paulo, Endocrine Neoplasia Unit, Instituto do, Av Dr Arnaldo 251, São Paulo, 01246-000, São Paulo, Brazil

    Ana O. Hoff

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kulke, M.H. (2011). Management of Metastatic Carcinoid Tumors. In: Yao, J., Hoff, P., Hoff, A. (eds) Neuroendocrine Tumors. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-60327-997-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-997-0_8

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-996-3

  • Online ISBN: 978-1-60327-997-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation